Nam, Anna S.
Dusaj, Neville http://orcid.org/0000-0002-4357-312X
Izzo, Franco http://orcid.org/0000-0002-5813-6504
Murali, Rekha
Myers, Robert M. http://orcid.org/0000-0003-1869-6467
Mouhieddine, Tarek H. http://orcid.org/0000-0002-1190-5978
Sotelo, Jesus
Benbarche, Salima http://orcid.org/0000-0001-5314-0435
Waarts, Michael
Gaiti, Federico http://orcid.org/0000-0001-5111-8816
Tahri, Sabrin
Levine, Ross http://orcid.org/0000-0002-7884-1905
Abdel-Wahab, Omar http://orcid.org/0000-0002-3907-6171
Godley, Lucy A.
Chaligne, Ronan http://orcid.org/0000-0003-4332-3291
Ghobrial, Irene http://orcid.org/0000-0001-7361-3092
Landau, Dan A. http://orcid.org/0000-0003-2346-9541
Article History
Received: 6 January 2022
Accepted: 29 July 2022
First Online: 22 September 2022
Competing interests
: O.A.-W. has served as a consultant for H3B Biomedicine, Foundation Medicine Inc., Merck Pfizer, and Janssen, and is on the scientific advisory board of Envisagenics Inc. and AIChemy; O.A.-W. has received prior research funding from H3B Biomedicine and LOXO Oncology unrelated to the current manuscript. I.G. serves on the advisory board of Bristol Myers Squibb, Takeda, Janssen, Sanofi and GlaxoSmithKline. D.A.L. has served as a consultant for Abbvie, AstraZeneca and Illumina, and is on the scientific advisory board of Mission Bio, Alethiomics, Pangea and C2i Genomics; D.A.L. has received prior research funding from BMS, 10x Genomics, Ultima Genomics, Abbvie and Illumina unrelated to the current manuscript.